Elicio Therapeutics, Inc. (ELTX): R&D Expense
$24.90M
Year ended 2025-12-31
$23.69M
Trailing 12 months to 2026-06-30
+11.2%
3-year compound annual growth
-8.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $24.90M | -26.0% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $33.66M | +41.1% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $23.85M | +31.7% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $18.10M | -62.8% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $48.70M | +24.9% | 2023-03-17, From 2021-01-01 |
| 2020-12-31 | $38.98M | n/a | 2022-03-30, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Elicio Therapeutics, Inc. (ELTX) | 2025-12-31 | $24.90M | -26.0% |
| BeyondSpring Inc. (BYSI) | 2025-12-31 | $4.39M | +66.0% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $6.31M | -29.3% |
| Onconetix, Inc. (ONCO) | 2024-12-31 | $154.4K | -92.1% |
| Aptevo Therapeutics Inc. (APVO) | 2025-12-31 | $14.54M | +1.1% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $5.44M | -14.8% |
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | $20.53M | +54.0% |
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $10.78M | +37.5% |
| Rein Therapeutics, Inc. (RNTX) | 2025-12-31 | $11.03M | -22.6% |
Compare ELTX, BYSI, CASIF, ONCO side by side · Screen every company in Pharmaceutical Preparations ↗